Skip to main content
. 2021 Nov 23;24(1):1–11. doi: 10.1016/j.neo.2021.11.009

Figure 4.

Figure 4

Unfolded protein response activation in response to bortezomib or K145 treatment is the same in wildtype and carfilzomib resistant myeloma cell lines. A) Venn diagram showing the overlap in genes up or downregulated in the 5TGM1.BR, 8226.BR, and 8226.CR cell lines compared to their drug-naïve counterparts from RNAseq analysis. B) 8226.wt, 8226.BR, and 8226.CR cells were cultured with carfilzomib for 4h, and then examined by Western blot for UPR proteins ATF4 and XBP1s. 8226.wt and 8226.CR cells were cultured with bortezomib (C) or K145 (D) for 4h, and then examined by Western blot for UPR proteins ATF4 and XBP1s. Dotted lines indicate where lanes from the same immunoblot have been spliced together to aid interpretation. Actin was used as a loading control. Data shown are representative of three independent experiments.